385 related articles for article (PubMed ID: 35434272)
1. Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors.
Yoon AR; Rivera-Cruz C; Gimble JM; Yun CO; Figueiredo ML
Mol Ther Oncolytics; 2022 Jun; 25():78-97. PubMed ID: 35434272
[TBL] [Abstract][Full Text] [Related]
2. Investigating the potential of oncolytic viruses for cancer treatment via MSC delivery.
Ghaleh HEG; Vakilzadeh G; Zahiri A; Farzanehpour M
Cell Commun Signal; 2023 Sep; 21(1):228. PubMed ID: 37667271
[TBL] [Abstract][Full Text] [Related]
3. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
Reale A; Calistri A; Altomonte J
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment.
Ghasemi Darestani N; Gilmanova AI; Al-Gazally ME; Zekiy AO; Ansari MJ; Zabibah RS; Jawad MA; Al-Shalah SAJ; Rizaev JA; Alnassar YS; Mohammed NM; Mustafa YF; Darvishi M; Akhavan-Sigari R
Cell Commun Signal; 2023 Feb; 21(1):43. PubMed ID: 36829187
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cells and oncolytic viruses: joining forces against cancer.
Moreno R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558278
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
7. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.
Ban W; Guan J; Huang H; He Z; Sun M; Liu F; Sun J
Nano Res; 2022; 15(5):4137-4153. PubMed ID: 35194488
[TBL] [Abstract][Full Text] [Related]
8. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses.
Ali S; Xia Q; Muhammad T; Liu L; Meng X; Bars-Cortina D; Khan AA; Huang Y; Dong L
Stem Cell Rev Rep; 2022 Feb; 18(2):523-543. PubMed ID: 34319509
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer.
Babaei A; Soleimanjahi H; Soleimani M; Arefian E
Biochem Pharmacol; 2021 Aug; 190():114644. PubMed ID: 34090878
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy.
Rahman MM; McFadden G
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771615
[TBL] [Abstract][Full Text] [Related]
13. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy.
Wang X; Zhao X; He Z
Oncol Lett; 2021 Apr; 21(4):238. PubMed ID: 33664802
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on immunotherapy via oncolytic viruses.
Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
[TBL] [Abstract][Full Text] [Related]
16. Advances in the clinical development of oncolytic viruses.
Li K; Zhao Y; Hu X; Jiao J; Wang W; Yao H
Am J Transl Res; 2022; 14(6):4192-4206. PubMed ID: 35836877
[TBL] [Abstract][Full Text] [Related]
17. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
Nguyen T; Avci NG; Shin DH; Martinez-Velez N; Jiang H
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29857493
[TBL] [Abstract][Full Text] [Related]
18. Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.
Fang C; Xiao G; Wang T; Song L; Peng B; Xu B; Zhang K
Research (Wash D C); 2023; 6():0108. PubMed ID: 37040283
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
20. Tumour vasculature: Friend or foe of oncolytic viruses?
Santry LA; van Vloten JP; Knapp JP; Matuszewska K; McAusland TM; Minott JA; Mould RC; Stegelmeier AA; Major PP; Wootton SK; Petrik JJ; Bridle BW
Cytokine Growth Factor Rev; 2020 Dec; 56():69-82. PubMed ID: 32893095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
